[PSA] cagrilintide is not what most of this community thinks it is
Writing this once so it can be linked instead of retyped: cagrilintide is not what most of this community thinks it is.
Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.
Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.
Sent a vial to Medutest because there was almost nothing on file for this compound. 99.4% against a claimed 98.5%, and I posted it because the log needs entries.
Ask me anything specific. Anything general I will probably get wrong.
best — the order this archive was captured in
Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing. Sparse data means wide uncertainty, not a verdict.
The engineering problem was duration: native amylin is short-acting and aggregation-prone. A long-acting analogue suitable for weekly administration is what makes the combination clinically interesting.
Carried an assumption over from the tirzepatide board and was corrected within an hour. Deserved.
Which receptor family are you attributing that effect to?
Agreed that the monotherapy numbers look modest out of context and that the context is the whole story.
Agreed — it is an amylin analogue and importing intuitions from the incretin boards produces confident nonsense.
[removed by moderator]
Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.
Do you have the publication or a summary of it?
Complementary mechanisms are the rationale for pairing: satiety signalling alongside incretin signalling, rather than more agonism at the same receptor.
Asked a question here that turned out to be based on a mechanism confusion. Three people untangled it patiently.
read the combination arms separately from the monotherapy arms
phase 3 data will change most of what gets said here
The tolerability tables were more informative than the headline numbers, which is usually the case and never how it gets summarised.
the interesting data is the combination, not the monotherapy
Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.
Left up. Thin evidence base, honestly labelled, which is the standard here.
I would not extrapolate the tolerability profile from the monotherapy arm to the combination. The trials report them separately for a reason.
Went looking for independent results on this and found a handful across the whole site. That is the honest state of the evidence.
Kept a log purely because so few people are logging this one. It is one person and it is not data.
Is there any independent purity data on this compound that you have seen?
Are you comparing against a GLP-1 monotherapy result? They are not comparable.
That is preclinical work and the thread is treating it as a human finding.
amylin and GLP-1 are not redundant pathways
What does the tolerability table in that paper actually say?
What does the tolerability table in that paper actually say?
Adding the standing caveat — nothing here is approved standalone and research material is not for human use.
Which trial and which readout?
nothing containing this is approved as a standalone product
How many separate lots has anyone here tested?
nausea profile in the combination trials is the thing to read carefully
- 1Combination and monotherapy arms must be read separately. Efficacy and…6 comments in this branch · started by u/nl_verzekering